NEW YORK – LabGenomics USA said Friday that it has acquired Integrated Molecular Diagnostics for an undisclosed amount.
The deal brings the number of LabGenomics USA's CLIA-certified laboratories in the US to four. Last year, the Rockville, Maryland-based firm acquired QDx Pathology, marking its entry into the US.
IMD provides services related to respiratory diseases, molecular diagnostics, and oncology with a particular focus on hematologic cancers and solid tumors. It also is collaborating with Cedars-Sinai Molecular Lab on a next-generation sequencing-based panel for solid tumors, which it plans to launch as a laboratory-developed test.
LabGenomics USA is a subsidiary of LabGenomics, headquartered in South Korea.
"We are committed to pioneering the US diagnostic market, aiming to introduce Korean diagnostics technologies," LabGenomics USA CEO Junghee Cho said in a statement. "By launching LDT services, we expect revenue growth and cost savings."